Latest news in cancer
Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA...
Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer
Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration...
Abemaciclib is approved by FDA with endocrine therapy for early breast cancer
October 2021: The Food and Drug Administration has approved abemaciclib (Verzenio, Eli Lilly and Company) in combination with endocrine therapy (tamoxifen or...
Brexucabtagene autoleucel is approved by FDA for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or...
Ruxolitinib is approved for chronic graft-versus-host disease
October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic...
Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer
October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid...
Cabozantinib is approved for differentiated thyroid cancer
October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age...
The FDA has given mobocertinib expedited approval for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or...
The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia
September 2021: For adult patients with Waldenström’s macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM). In ASPEN...
Ivosidenib has been approved by the FDA for advanced or metastatic cholangiocarcinoma
Sept 19, 2021: The Food and Drug Administration approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally...
TECARTUS (brexucabtagene autoleucel) – CAR T treatment for relapsed or refractory mantle cell lymphoma
July 25, 2021: Kite, a Gilead Company (Nasdaq: GILD), today announced that the FDA has granted TecartusTM (brexucabtagene autoleucel, formerly KTE-X19), the...
Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.